G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a KCa1.1 (BKCa)-dependent mechanisms

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 3, 2014, Pages 421-431

  Fryer, Ryan M ^a   Ng, Khing Jow ^a   Nodop Mazurek, Suzanne G ^a   Patnaude, Lori ^a   Skow, Donna J ^a   Muthukumarana, Akalushi ^a   Gilpin, Kyle E ^a   Dinallo, Roger M ^a   Kuzmich, Daniel ^a   Lord, John ^a   Sanyal, Sulagna ^a   Yu, Hui ^a   Harcken, Christian ^a   Cerny, Matthew C ^a   Hickey, Eugene R ^a   Modis, Louise K ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [9 [3 (4 CHLORO PHENYL) 5 METHYL 3H IMIDAZOLE 4 CARBONYL] 9 AZA BICYCLO[3.3.1]NON 3 YL] N,N DIMETHYLBENZAMIDE; BILE ACID; COMPOUND 12; COMPOUND 16; G PROTEIN COUPLED BILE ACID RECEPTOR 1; G PROTEIN COUPLED BILE ACID RECEPTOR 1 AGONIST; G PROTEIN COUPLED RECEPTOR; IBERIOTOXIN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; LEVOTHYROXINE; NITRIC OXIDE; SALAZOSULFAPYRIDINE; THYROXINE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; CARDIOVASCULAR FUNCTION; COLITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOG; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; EX VIVO STUDY; HEART OUTPUT; HUMAN; IN VIVO STUDY; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; TACHYCARDIA; VASCULAR RING;

ANIMALS; ARTERIES; ATRIAL NATRIURETIC FACTOR; CHO CELLS; COLITIS; CRICETINAE; CRICETULUS; CYCLIC AMP; CYTOKINES; DINITROFLUOROBENZENE; DOGS; ENDOTHELIN-1; HUMANS; IMIDAZOLES; MALE; NITRIC OXIDE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; THYROXINE; TRIAZOLES; VASODILATION;

EID: 84896730426     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.210005     Document Type: Article

References (53)

1. Banfor PN, Franklin PA, Segreti JA, Widomski DL, Davidsen SK, Albert DH, Cox BF, Fryer RM, and Gintant GA (2009) ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol 53:173-178.
2. Banfor PN, Preusser LC, Campbell TJ, Marsh KC, Polakowski JS, Reinhart GA, Cox BF, and Fryer RM (2008) Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol 294:H238-H248.
3. Bianco AC and Kim BW (2006) Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 116:2571-2579.
4. Bogin E, Better O, and Harari I (1983) The effect of jaundiced sera and bile salts on cultured beating rat heart cells. Experientia 39:1307-1308.
5. Bukiya AN, Liu J, Toro L, and Dopico AM (2007) Beta1 (KCNMB1) subunits mediate lithocholate activation of large-conductance Ca21-activated K1 channels and dilation in small, resistance-size arteries. Mol Pharmacol 72:359-369.
6. Cini G, Carpi A, Mechanick J, Cini L, Camici M, Galetta F, Giardino R, Russo MA, and Iervasi G (2009) Thyroid hormones and the cardiovascular system: pathophysiology and interventions. Biomed Pharmacother 63:742-753.
7. Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A, and Fiorucci S (2011) The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE 6:e25637.
8. Danzi S and Klein I (2012) Thyroid hormone and the cardiovascular system. Med Clin North Am 96:257-268.
9. Desai MS, Shabier Z, Taylor M, Lam F, Thevananther S, Kosters A, and Karpen SJ (2010) Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. Hepatology 51:2097-2107.
10. Dopico AM, Walsh JV, Jr, and Singer JJ (2002) Natural bile acids and synthetic analogues modulate large conductance Ca21-activated K1 (BKCa) channel activity in smooth muscle cells. J Gen Physiol 119:251-273.
11. Fazio S, Palmieri EA, Lombardi G, and Biondi B (2004) Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 59:31-50.
12. Félétou M and Vanhoutte PM (2000) Endothelium-dependent hyperpolarization of vascular smooth muscle cells. Acta Pharmacol Sin 21:1-18.
13. Franklin PH, Banfor PN, Tapang P, Segreti JA, Widomski DL, Larson KJ, Noonan WT, Gintant GA, Davidsen SK, and Albert DH, et al. (2009) Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H- indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. J Pharmacol Exp Ther 329:928-937.
14. Fryer RM, Harrison PC, Muthukumarana A, Nodop Mazurek SG, Ng KJ, Chen RR, Harrington KE, Dinallo RM, Chi L, and Reinhart GA (2012a) Strategic integration of in vivo cardiovascular models during lead optimization: predictive value of 4 models independent of species, route of administration, and influence of anesthesia. J Cardiovasc Pharmacol 59:369-376.
15. Fryer RM, Muthukumarana A, Chen RR, Smith JD, Mazurek SN, Harrington KE, Dinallo RM, Burke J, DiCapua FM, and Guo X, et al. (2012b) Mitigation of offtarget adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors. J Pharmacol Exp Ther 340:492-500.
16. 3) in rat. PLoS ONE 7: e52985.
17. Fryer RM, Preusser LC, Calzadilla SV, Hu Y, Xu H, Marsh KC, Cox BF, Lin CT, Gopalakrishnan M, and Reinhart GA (2004) (-)-(9S)-9-(3-Bromo-4-fluorophenyl) -2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine. J Cardiovasc Pharmacol 44: 137-147.
18. Futatsugi K, Bahnck KB, Brenner MB, Buxton J, Chin JE, Coffey SB, Dubins J, Flynn D, Gautreau D, Guzman-Perez A, et al. (2012) Optimization of triazole-based TGR5 agonists towards orally available agents. Med Chem Commun 4:205-210.
19. Galvez A, Gimenez-Gallego G, Reuben JP, Roy-Contancin L, Feigenbaum P, Kaczorowski GJ, and Garcia ML (1990) Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus. J Biol Chem 265:11083-11090.
20. Gorelik J, Harding SE, Shevchuk AI, Koralage D, Lab M, de Swiet M, Korchev Y, and Williamson C (2002) Taurocholate induces changes in rat cardiomyocyte contraction and calcium dynamics. Clin Sci (Lond) 103:191-200.
21. Haselow K, Bode JG, Wammers M, Ehlting C, Keitel V, Kleinebrecht L, Schupp AK, Häussinger D, and Graf D (2013) Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages. J Leukoc Biol 94:1253-1264.
22. Hawkins JV, Emmel EL, Feuer JJ, Nedelman MA, Harvey CJ, Klein HJ, Rozmiarek H, Kennedy AR, Lichtenstein GR, and Billings PC (1997) Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig Dis Sci 42:1969-1980.
23. He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, and Watkins S, et al. (2006) Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res 98:192-199.
24. Hodge RJ, Lin J, Vasit Johnson LS, Gould EP, Bowers GD, and Nunez DJ (2013) Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes. Clin Pharmacol Drug Devel 2:213-222.
25. Jackson WF (2005) Potassium channels in the peripheral microcirculation. Microcirculation 12:113-127.
26. Joubert P (1978a) An in vivo investigation of the negative chronotropic effect of cholic acid in the rat. Clin Exp Pharmacol Physiol 5:1-8.
27. Joubert P (1978b) Cholic acid and the heart: in vitro studies of the effect on heart rate and myocardial contractility in the rat. Clin Exp Pharmacol Physiol 5:9-16.
28. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, and Shintani Y, et al. (2003) A G protein-coupled receptor responsive to bile acids. J Biol Chem 278:9435-9440.
29. Keitel V, Reinehr R, Gatsios P, Rupprecht C, Görg B, Selbach O, Häussinger D, and Kubitz R (2007) The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45:695-704.
30. Khurana S, Raufman JP, and Pallone TL (2011) Bile acids regulate cardiovascular function. Clin Transl Sci 4:210-218.
31. Kida T, Murata T, Hori M, and Ozaki H (2009) Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle. Am J Physiol Heart Circ Physiol 296:H195-H201.
32. Ko EA, Han J, Jung ID, and Park WS (2008) Physiological roles of K1 channels in vascular smooth muscle cells. J Smooth Muscle Res 44:65-81.
33. Kym PR, Souers AJ, Campbell TJ, Lynch JK, Judd AS, Iyengar R, Vasudevan A, Gao J, Freeman JC, and Wodka D, et al. (2006) Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists. J Med Chem 49:2339-2352.
34. Lavoie B, Balemba OB, Godfrey C, Watson CA, Vassileva G, Corvera CU, Nelson MT, and Mawe GM (2010) Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. J Physiol 588:3295-3305.
35. Li J, Wilson A, Kuruba R, Zhang Q, Gao X, He F, Zhang LM, Pitt BR, Xie W, and Li S (2008) FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res 77:169-177.
36. Liard JF (1994) L-NAME antagonizes vasopressin V2-induced vasodilatation in dogs. Am J Physiol 266:H99-H106.
37. Martín R, Carvalho-Tavares J, Hernández M, Arnés M, Ruiz-Gutiérrez V, and Nieto ML (2010) Beneficial actions of oleanolic acid in an experimental model of multiple sclerosis: a potential therapeutic role. Biochem Pharmacol 79:198-208.
38. Martínez-Ródenas F, Pereira JA, Jiménez W, Gubern JM, and Sitges-Serra A (1998) Circulating bile is the main factor responsible for atrial natriuretic peptide release in experimental obstructive jaundice. Br J Surg 85:480-484.
39. Maruyama M (2010) inventor, Takeda Pharmaceutical Company Limited, assignee. Therapeutic agent for irritable bowel syndrome. Patent no. PCT/JP2009/063960 (WO 2010/016552 Al), 174. 2010 Nov 2.
40. Nakajima T, Okuda Y, Chisaki K, Shin WS, Iwasawa K, Morita T, Matsumoto A, Suzuki JI, Suzuki S, and Yamada N, et al. (2000) Bile acids increase intracellular Ca(21) concentration and nitric oxide production in vascular endothelial cells. Br J Pharmacol 130:1457-1467.
41. Newby DE and Hayes PC (2002) Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but 'splanchnic steal'. QJM 95:827-830.
42. Orsini M (2013) TGR5 in metabolic diseases. Presented at the 11th Annual Discovery on Target: GPCR-Targeted Therapeutics Conference; 2013 Sep 24-26;
43. Boston, MA. Pak JM, Adeagbo AS, Triggle CR, Shaffer EA, and Lee SS (1994) Mechanism of bile salt vasoactivity: dependence on calcium channels in vascular smooth muscle. Br J Pharmacol 112:1209-1215.
44. Pak JM and Lee SS (1993) Vasoactive effects of bile salts in cirrhotic rats: in vivo and in vitro studies. Hepatology 18:1175-1181.
45. Piotrowski DW, Futatsugi K, Warmus JS, Orr STM, Freeman-Cook KD, Londregan AT, Wei L, Jennings SM, Herr M, Coffey SB, et al. (2012) Identification of tetrahydropyrido[4,3-d]pyrimidine amides as a new class of orally bioavailable TGR5 agonists. ACS Med Chem Lett 4:63-68.
46. Pols TW, Nomura M, Harach T, Lo Sasso G, Oosterveer MH, Thomas C, Rizzo G, Gioiello A, Adorini L, and Pellicciari R, et al. (2011a) TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 14:747-757.
47. Pols TW, Noriega LG, Nomura M, Auwerx J, and Schoonjans K (2011b) The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 54:1263-1272.
48. Preusser LC, Fryer RM, Gerhardt A, Hu Y, Delgado-Herrera L, Melnick JZ, Williams LA, Cox BF, and Reinhart GA (2005) Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents. Clin Exp Pharmacol Physiol 32:1020-1026.
49. Robertson RM and Roberson D (1995) drugs used for the treatment of myocardial ischemia, In: Goodman & Gillman's The Pharmacological Basis of Therapeutics, New York, McGraw-Hill Companies, pp 759-779
50. Sheikh Abdul Kadir SH, Miragoli M, Abu-Hayyeh S, Moshkov AV, Xie Q, Keitel V, Nikolaev VO, Williamson C, and Gorelik J (2010) Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes. PLoS ONE 5:e9689.
51. Wang YD, Chen WD, Yu D, Forman BM, and Huang W (2011) The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor k light-chain enhancer of activated B cells (NF-kB) in mice. Hepatology 54:1421-1432.
52. Williamson C, Gorelik J, Eaton BM, Lab M, de Swiet M, and Korchev Y (2001) The bile acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis. Clin Sci (Lond) 100:363-369.
53. Yoneno K, Hisamatsu T, Shimamura K, Kamada N, Ichikawa R, Kitazume MT, Mori M, Uo M, Namikawa Y, and Matsuoka K, et al. (2013) TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. Immunology 139:19-29.